Patient with colorectal cancer with heterogeneous KRAS molecular status responding to cetuximab-based chemotherapy

Journal of Clinical Oncology

Volumn 28, Issue 36, 2010, Pages

  Mancuso, Andrea ^a   Sollami, Rossella ^a   Recine, Federica ^a   Cerbone, Linda ^b   Macciomei, Maria Cristina ^a   Leone, Alvaro ^a  

^a SAN CAMILLO FORLANINI HOSPITAL   (Italy)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; K RAS PROTEIN;

AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER STAGING; CASE REPORT; COLORECTAL CANCER; HUMAN; IMMUNOHISTOCHEMISTRY; LIVER METASTASIS; MALE; MORPHOLOGY; MULTIPLE CYCLE TREATMENT; MUTATION; PERITONEUM METASTASIS; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; PROTEIN EXPRESSION; SEQUENCE ANALYSIS;

ADENOCARCINOMA; AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; COLORECTAL NEOPLASMS; HUMANS; MALE; PROTO-ONCOGENE PROTEINS; RAS PROTEINS;

EID: 79951864807     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2010.30.5011     Document Type: Article

References (20)

1. Karapetis CS, Khambata-Ford S, Jonker DJ, et al: K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 359:1757-1765, 2008
2. Jemal A, Siegel R, Ward E, et al: Cancer statistics, CA Cancer J Clin 58:71-96, 2008
3. Penna C, Nordlinger B: Colorectal metastasis (liver and lung). Surg Clin North Am 82: 1075-1090, x-xi, 2002
4. Fong Y, Cohen AM, Fortner JG, et al: Liver resection for colorectal metastases. J Clin Oncol 15:938-946, 1997 (Pubitemid 27106275)
5. Lockhart AC, Berlin JD: The epidermal growth factor receptor as a target for colorectal cancer therapy. Semin Oncol 32:52-60, 2005
6. Jean GW, Shah SR: Epidermal growth factor receptor monoclonal antibodies for the treatment of metastatic colorectal cancer. Pharmacotherapy 28:742-754, 2008 (Pubitemid 351975378)
7. Tabernero J, Van Cutsem E, Diaz-Rubio E, et al: Phase II trial of cetuximab in combination with fluorouracil, leucovorin, and oxaliplatin in the first-line treatment of metastatic colorectal cancer. J Clin Oncol 25:5225-5232, 2007 (Pubitemid 350232254)
8. Grandal MV, Madshus IH: Epidermal growth factor receptor and cancer: Control of oncogenic signalling by endocytosis. J Cell Mol Med 12:1527-1534, 2008
9. Fransen K, Klintenas M, Osterstrom A, et al: Mutation analysis of the BRAF, ARAF and RAF-1 genes in human colorectal adenocarcinomas. Carcinogenesis 25:527-533, 2004
10. Bardelli A, Siena S: Molecular mechanisms of resistance to cetuximab and panitumumab in colorectal cancer. J Clin Oncol 28:1181-1189, 2010
11. Barbacid M: Ras genes. Annu Rev Biochem 56:779-827, 1987
12. Wong R, Cunningham D: Using predictive biomarkers to select patients with advanced colorectal cancer for treatment with epidermal growth factor receptor antibodies. J Clin Oncol 26:5668-5670, 2008
13. Amado RG, Wolf M, Peeters M, et al: Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 26:1626-1634, 2008
14. Vogelstein B, Fearon ER, Hamilton SR, et al: Genetic alterations during colorectal-tumor development. N Engl J Med 319:525-532, 1988
15. Santini D, Loupakis F, Vincenzi B, et al: High concordance of KRAS status between primary colorectal tumors and related metastatic sites: Implications for clinical practice. Oncologist 13:1270-1275, 2008
16. Etienne-Grimaldi MC, Formento JL, Francoual M, et al: K-Ras mutations and treatment outcome in colorectal cancer patients receiving exclusive fluoropyrimidine therapy. Clin Cancer Res 14:4830-4835, 2008
17. Folprecht G, Gruenberger T, Bechstein WO, et al: Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: The CELIM randomised phase 2 trial. Lancet Oncol 11:38-47, 2010
18. Baldus SE, Schaefer KL, Engers R, et al: Prevalence and heterogeneity of KRAS, BRAF, and PIK3CA mutations in primary colorectal adenocarcinomas and their corresponding metastases. Clin Cancer Res 16:790-799, 2010
19. Artale S, Sartore-Bianchi A, Veronese SM, et al: Mutations of KRAS and BRAF in primary and matched metastatic sites of colorectal cancer. J Clin Oncol 26:4217-4421, 2008
20. Goranova TE, Ohue M, Kato K: Putative precursor cancer cells in human colorectal cancer tissue. Int J Clin Exp Pathol 2:154-162, 2009